Terry has been leading successful drug discovery and development organizations in the biotechnology and pharmaceutical industries for more than 30 years. In 2015, he co-founded Arcus, a drug discovery company focused on the treatment of cancer by blocking tumor-induced immunosuppression. Previously, Terry was co-founder and CEO of Flexus Biosciences, focusing on small molecule drugs that reverse tumor immunosuppression. He has held several executive positions at Amgen and Tularik, as well as scientific and management positions at Pfizer and Abbott Laboratories. Terry also serves on the boards of scientific institutions such as the Salk Institute Board of Trustees and the Caltech Biology & Engineering Chair’s Council.
Aaron is the Founder of Simcha Therapeutics and a widely-recognized leader in cytokine engineering for which he was named to Endpoints “20 under 40 in Biopharma in 2022” and Nature Biotechnology’s “Top 20 Translational Researchers of 2020.” He led the development of decoy-resistant IL-18 in his laboratory at the Yale School of Medicine where he is an Associate Professor of Immunobiology.
Sean has over 10 years of combined experience in business development, investment, and research at big pharma and institutes. Sean is currently Director of investment at WuXi AppTec. He has served on the boards of six biotech companies and was a business development leader at AstraZeneca Oncology Medical, China and at CSPC Pharmaceutical Group.
Simeon is CEO and Managing Partner of SR One, with overall responsibility for the fund and is Chair of the Investment Committee. Simeon joined SR One in 2007 and established its San Francisco office in 2010. Previously, he worked in management consulting (Bain & Co.) and investment banking (Goldman Sachs). Simeon led SR One’s investments in several marquee deals including CRISPR Therapeutics (CRSP), Principia Biopharma (PRNB), Turning Point Therapeutics (TPTX), Progyny (PGNY), and Nkarta Therapeutics (NKTX), which he co-founded.
Simeon has a BA from the Johns Hopkins University and an MD/MBA from the University of Pennsylvania School of Medicine/The Wharton School.
Jake is a Venture Partner at ARCH Venture Partners and SR One Capital Management. Prior to MyoKardia Inc.’s acquisition by Bristol Myers Squibb in November 2020, Jake served as the Chief Business Officer of MyoKardia. Prior to this, he served as Senior Vice President, Finance and Corporate Development and Principal Financial Officer of MyoKardia having joined the company in 2014.
In earlier roles, Jake served as Vice President, Business Operations and head of corporate development at Ablexis, LLC and as a principal at Third Rock Ventures. While at Third Rock Ventures, he was actively involved in a variety of leading biopharmaceutical companies including Agios Pharmaceuticals, Inc., CytomX Therapeutics Inc., and Global Blood Therapeutics, Inc. Previously, Jake served in roles in the investment group at Royalty Pharma, the business development group at Endo Pharmaceuticals Inc. and as a management consultant at Putnam Associates.
In addition to Simcha, he currently serves on the board of Arya Sciences Acquisition Corp V, Attralus, Enliven and Phoenix Tissue Repair, Inc.
Jake holds a B.S. in biology and a B.A. in economics from Duke University and an M.B.A. from Harvard Business School.
Sanuj has spent more than 20 years in strategic and operational roles across the life science industry, both as an investor and company builder. Most recently, he served as CEO-in-residence at BridgeBio (BBIO) where he was chief executive officer of PellePharm, and executive chair of Phoenix Tissue Repair. In these roles, Sanuj led both companies’ growth, directed strategy, secured significant partnerships, and advanced pipeline programs in oncology and rare skin diseases through mid- and late-stage clinical trials. Before this, he served as chief business officer at aTyr Pharma (LIFE), a clinical-stage protein therapeutics company focused on tRNA synthetases. Prior to that, Sanuj was senior vice president of corporate development at The Medicines Company (MDCO), where he led multiple transactions totaling more than $2 billion in potential value. Sanuj began his biotech career as a venture capitalist for 10 years with Burrill & Company, Radius Ventures, and Asian Healthcare Fund.
Sanuj was previously a practicing physician, board-certified in Internal Medicine, having completed his residency training at Thomas Jefferson University Hospital. He received his bachelor’s degree from Northwestern University, his doctorate in medicine from Jefferson Medical College, and his master’s of business administration from the Kellogg School of Management.